Medico — August 2024
-
GN får skåret kursmålet hos Nordea https://proinvestor.com/investornyt/1199016/gn-far-skaret-kursmalet-hos-nordea
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1199525/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Demant lander en spids over det ventede i stort set kendt regnskab https://proinvestor.com/investornyt/1200608/dmant-lander-en-spids-over-det-ventede-i-stort-set-kendt-regnskab
-
Demant får sænket kursmål hos JP Morgan til 319 kr. fra 381 kr. https://proinvestor.com/investornyt/1201135/demant-far-saenket-kursmal-hos-jp-morgan-til-319-kr-fra-381-kr
-
GN og Demant taber fortsat markedsandele på markedet for amerikanske veteraner https://proinvestor.com/investornyt/1201152/gn-og-demant-taber-fortsat-markedsandele-pa-markedet-for-amerikanske-veteraner
-
Coloplast skuffer på driften og overskuddet trods gode takter på toplinjen https://proinvestor.com/investornyt/1202509/coloplast-skuffer-pa-driften-og-overskuddet-trods-gode-takter-pa-toplinjen
-
Demant: Morgan Stanley løfter anbefalingen løftes to hak til "overvægt" https://proinvestor.com/investornyt/1203034/demant-morgan-stanley-lofter-anbefalingen-loftes-to-hak-til-overvaegt
-
Coloplast får løftet kursmålet med 5 pct. til 1050 kr. hos Jefferies https://proinvestor.com/investornyt/1203035/coloplast-far-loftet-kursmalet-med-5-pct-til-1050-kr-hos-jefferies
-
GN voksede mindre end ventet på top- og bundlinje https://proinvestor.com/investornyt/1203556/gn-voksede-mindre-end-ventet-pa-top-og-budnlinje
-
GN Store Nord: Et regnskab med mislydehttps://proinvestor.com/boards/121883
-
forside
nyhederGN-topchef: Vi fokuserer på alt det vi selv kan kontrollere https://proinvestor.com/investornyt/1203565/gn-topchef-vi-fokuserer-pa-alt-det-vi-selv-kan-kontrollere
-
Demants anbefaling løftes til neutralt territorium hos Jefferies https://proinvestor.com/investornyt/1204080/demants-anbefaling-loftes-til-neutralt-territorium-hos-jefferies
-
GN får tage toppen af kursmål hos DNB https://proinvestor.com/investornyt/1204078/gn-far-tage-toppen-af-kursmal-hos-dnb
-
GN's kursmål skåret knap 6 pct. af Carnegie https://proinvestor.com/investornyt/1204079/gns-kursmal-skaret-knap-6-pct-af-carnegie
-
GN's kursmål reduceres af Morgan Stanley https://proinvestor.com/investornyt/1204076/gns-kursmal-reduceres-af-morgan-stanley
-
Novonesis sænkes til "hold" hos Carnegie https://proinvestor.com/investornyt/1205004/novonesis-saenkes-til-hold-hos-carnegie
-
Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.
The 2024 outlook is increased to:
• Pro forma organic sales growth of now 7-8% (previously “upper end of 5-7%”)
• Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously “35-36%”)
Additional information is made available in the Company announcement: Interim Report H1 2024.
-
Novonesis vil udbetale udbytte på 2 kr. per aktie https://proinvestor.com/investornyt/1205769/novonesis-vil-udbetale-udbytte-pa-2-kr-per-aktie
-
Novonesis leverer tocifret vækst i andet kvartal og opjusterer forventningerne https://proinvestor.com/investornyt/1205783/novonesis-leverer-tocifret-vaekst-i-andet-kvartal-og-opjusterer-forventningerne
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind